Financial reports
10-Q
2024 Q1
Quarterly report
13 Feb 24
10-K
2023 FY
Annual report
12 Dec 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
10-Q
2023 Q2
Quarterly report
9 May 23
10-Q
2022 Q1
Quarterly report
7 Feb 23
10-K
2022 FY
Annual report
13 Dec 22
10-Q
2022 Q3
Quarterly report
4 Aug 22
10-Q
2022 Q2
Quarterly report
10 May 22
10-Q
2022 Q1
Quarterly report
3 Feb 22
10-K
2021 FY
Annual report
18 Nov 21
Current reports
8-K
Submission of Matters to a Vote of Security Holders
7 Mar 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
29 Jan 24
8-K
Results of Operations and Financial Condition
12 Dec 23
8-K
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
6 Nov 23
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
26 Oct 23
8-K
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
23 Oct 23
8-K
Updated Phase 1 results selected for a poster presentation at ESMO 2023
18 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Sep 23
8-K
ESSA Pharma Provides Corporate Update and Reports Financial Results for Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing
8 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
5 Apr 24
424B5
Prospectus supplement for primary offering
3 Nov 23
S-3/A
Shelf registration (amended)
3 Oct 23
S-3
Shelf registration
19 Sep 23
S-8
Registration of securities for employees
1 Oct 21
S-3ASR
Automatic shelf registration
21 Jun 21
424B5
Prospectus supplement for primary offering
18 Feb 21
424B5
Prospectus supplement for primary offering
16 Feb 21
S-3/A
Shelf registration (amended)
23 Dec 20
S-3/A
Shelf registration (amended)
23 Dec 20
Other
EFFECT
Notice of effectiveness
11 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
CORRESP
Correspondence with SEC
3 Oct 23
UPLOAD
Letter from SEC
26 Sep 23
EFFECT
Notice of effectiveness
30 Dec 20
EFFECT
Notice of effectiveness
30 Dec 20
CORRESP
Correspondence with SEC
23 Dec 20
CORRESP
Correspondence with SEC
23 Dec 20
CORRESP
Correspondence with SEC
23 Dec 20
Ownership
4
Richard M Glickman
25 Apr 24
4
Peter Virsik
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
4
SANFORD S ZWEIFACH
28 Mar 24
4
Marella Thorell
28 Mar 24
4
Gary Sollis
28 Mar 24
4
Scott Requadt
28 Mar 24
4
Lauren Merendino
28 Mar 24
4
John Alexander Martin
28 Mar 24
4
Philip W. Kantoff
28 Mar 24